Literature DB >> 33268959

First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

Maryam Alkhatry1, Ahmad Al-Rifai2, Vito Annese3, Filippos Georgopoulos4, Ahmad N Jazzar5, Ahmed M Khassouan6, Zaher Koutoubi7, Rahul Nathwani8, Mazen S Taha9, Jimmy K Limdi10.   

Abstract

Ulcerative colitis and Crohn's disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract. The incidence and prevalence are on the rise worldwide, and the heterogeneity between patients and within individuals over time is striking. The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients. This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence- and expert opinion-based recommendations. Comprehensive up-to-date guidance is provided regarding diagnosis, evaluation of disease severity, appropriate and timely use of different investigations, choice of appropriate therapy for induction and remission phase according to disease severity, and management of main complications. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Adalimumab; Crohn’s disease; Infliximab; Tofacitinib; Ulcerative colitis; Ustekinumab; Vedolizumab

Mesh：

Year:  2020        PMID： 33268959      PMCID： PMC7684461          DOI： 10.3748/wjg.v26.i43.6710

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  478 in total

1.  Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): a multicenter prospective study.

Authors:  Y Niv; S Ilani; Z Levi; M Hershkowitz; E Niv; Z Fireman; S O'Donnel; C O'Morain; R Eliakim; E Scapa; N Kalantzis; C Kalantzis; P Apostolopoulos; E Gal
Journal:  Endoscopy       Date:  2011-11-28       Impact factor: 10.093

2.  Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.

Authors:  Theodore Rokkas; Piero Portincasa; Ioannis E Koutroubakis
Journal:  J Gastrointestin Liver Dis       Date:  2018-09       Impact factor: 2.008

3.  Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Authors:  Neeraj Narula; Farhad Peerani; Joseph Meserve; Gursimran Kochhar; Khadija Chaudrey; Justin Hartke; Prianka Chilukuri; Jenna Koliani-Pace; Adam Winters; Leah Katta; Eugenia Shmidt; Robert Hirten; David Faleck; Malav P Parikh; Diana Whitehead; Brigid S Boland; Siddharth Singh; Sashidhar Varma Sagi; Monika Fischer; Shannon Chang; Morris Barocas; Michelle Luo; Karen Lasch; Matthew Bohm; Dana Lukin; Keith Sultan; Arun Swaminath; David Hudesman; Nitin Gupta; Bo Shen; Sunanda Kane; Edward V Loftus; Corey A Siegel; Bruce E Sands; Jean-Frederic Colombel; William J Sandborn; Parambir S Dulai
Journal:  Am J Gastroenterol       Date:  2018-06-27       Impact factor: 10.864

4.  Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.

Authors:  Johan Burisch; Gediminas Kiudelis; Limas Kupcinskas; Hendrika Adriana Linda Kievit; Karina Winther Andersen; Vibeke Andersen; Riina Salupere; Natalia Pedersen; Jens Kjeldsen; Renata D'Incà; Daniela Valpiani; Doron Schwartz; Selwyn Odes; Jóngerð Olsen; Kári Rubek Nielsen; Zsuzsanna Vegh; Peter Laszlo Lakatos; Alina Toca; Svetlana Turcan; Konstantinos H Katsanos; Dimitrios K Christodoulou; Mathurin Fumery; Corinne Gower-Rousseau; Stefania Chetcuti Zammit; Pierre Ellul; Carl Eriksson; Jonas Halfvarson; Fernando Jose Magro; Dana Duricova; Martin Bortlik; Alberto Fernandez; Vicent Hernández; Sally Myers; Shaji Sebastian; Pia Oksanen; Pekka Collin; Adrian Goldis; Ravi Misra; Naila Arebi; Ioannis P Kaimakliotis; Inna Nikuina; Elena Belousova; Marko Brinar; Silvija Cukovic-Cavka; Ebbe Langholz; Pia Munkholm
Journal:  Gut       Date:  2018-01-23       Impact factor: 23.059

5.  A Diagnostic Accuracy Meta-analysis of CT and MRI for the Evaluation of Small Bowel Crohn Disease.

Authors:  Wenhong Liu; Jincai Liu; Wenlian Xiao; Guanghua Luo
Journal:  Acad Radiol       Date:  2017-06-05       Impact factor: 3.173

6.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

7.  Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease.

Authors:  Dario Sorrentino; Alberto Paviotti; Giovanni Terrosu; Claudio Avellini; Marco Geraci; Dimitra Zarifi
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-04       Impact factor: 11.382

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 9.  Interventions for prevention of post-operative recurrence of Crohn's disease.

Authors:  Glen Doherty; Gayle Bennett; Seema Patil; Adam Cheifetz; Alan C Moss
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 10.  Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.

Authors:  S Danese; C A Siegel; L Peyrin-Biroulet
Journal:  Aliment Pharmacol Ther       Date:  2014-03-19       Impact factor: 8.171
View more
  5 in total

Review 1.  A review of the therapeutic management of Crohn's disease.

Authors:  Aditi Kumar; Alexander Cole; Jonathan Segal; Philip Smith; Jimmy K Limdi
Journal:  Therap Adv Gastroenterol       Date:  2022-02-17       Impact factor: 4.409

2.  Combination of serological biomarkers and clinical features to predict mucosal healing in Crohn's disease: a multicenter cohort study.

Authors:  Nana Tang; Han Chen; Ruidong Chen; Wen Tang; Hongjie Zhang
Journal:  BMC Gastroenterol       Date:  2022-05-10       Impact factor: 2.847

3.  Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates.

Authors:  Vito Annese; Rahul Nathwani; Maryam Alkhatry; Ahmad Al-Rifai; Sameer Al Awadhi; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Mazen S Taha; Jimmy K Limdi
Journal:  Therap Adv Gastroenterol       Date:  2021-12-22       Impact factor: 4.409

4.  Predicting Mucosal Healing in Crohn's Disease: A Nomogram Model Developed from a Retrospective Cohort.

Authors:  Nana Tang; Han Chen; Ruidong Chen; Wen Tang; Hongjie Zhang
Journal:  J Inflamm Res       Date:  2022-09-23

5.  Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease.

Authors:  Omeed Alipour; Alakh Gualti; Ling Shao; Bing Zhang
Journal:  BMC Gastroenterol       Date:  2021-08-03       Impact factor: 3.067
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.